The experimental agent, called Pro-LYTAC, belongs to a class of compounds known as lysosome-targeting chimeras, or LYTACs. These molecules are designed to eliminate selected proteins from the surface of cells rather than merely block their activity. A LYTAC typically combines a targeting component that recognizes a cell-surface protein with a ligand capable of engaging the cell’s lysosomal trafficking machinery. Once the complex is internalized, the lysosome—an organelle filled with enzymes that digest proteins and other cellular material—breaks down the targeted protein. This approach is potentially powerful because it can remove disease-promoting proteins that are difficult to inhibit with conventional small-molecule drugs.

The researchers led by Peng Shi and Mohan Chen sought to make this protein-degradation technology more selective by placing it behind a molecular gate. Their Pro-LYTAC is activated by glutathione, a small antioxidant peptide present in cells throughout the body but found at elevated concentrations in many tumors. Glutathione helps maintain the reducing environment inside cells and participates in the detoxification of reactive chemical compounds. By incorporating a glutathione-responsive chemical “cage” into the therapeutic design, the team aimed to prevent the active LYTAC structure from functioning until it encountered the biochemical conditions associated with malignant tissue. In principle, the inactive form can circulate without efficiently binding its target or engaging lysosomal uptake pathways, while the tumor-associated glutathione environment removes the protective lock.

This design transforms a feature of tumor biology into a molecular switch. Cancer cells frequently exhibit altered redox metabolism, increased antioxidant capacity and distinctive concentrations of intracellular metabolites. These differences are not universal across every tumor type, but they can provide chemical signals that are less pronounced in healthy tissues. In the Pro-LYTAC strategy, glutathione serves as the trigger that converts a relatively inert conjugate into a protein-degrading agent. The researchers constructed the therapeutic as a caged glycan-antibody conjugate, linking an antibody-based recognition element with a glycan component that can direct the complex toward lysosomal clearance. The cage is intended to reduce activity before activation, thereby limiting exposure of healthy organs to the fully functional degrader.

After the molecular lock is removed, Pro-LYTAC targets a protein that cancer cells use to avoid immune recognition. Many tumors survive in the body not only because they divide uncontrollably but also because they actively suppress or evade immune attack. Surface proteins involved in immune checkpoint signaling can function as protective shields, transmitting signals that prevent immune cells from efficiently identifying malignant cells as dangerous. By directing one of these immune-evasion proteins to the lysosome, Pro-LYTAC causes its physical removal from the cancer-cell surface. The result is not simply temporary inhibition of a protein’s activity; it is degradation of the protein itself, potentially producing a more sustained change in the cell’s interaction with the immune system.

The researchers evaluated the therapeutic in mouse models of triple-negative breast cancer, an aggressive disease subtype that lacks three commonly exploited molecular targets and therefore remains difficult to treat. During the two-week study, animals receiving Pro-LYTAC showed stronger tumor suppression than control animals treated with saline. The findings indicate that the compound was able to reach tumors, become activated under tumor-associated conditions and engage the intended protein-degradation pathway. Removing the immune-evasion shield is expected to make tumor cells more visible to immune defenses, allowing immune cells to recognize and attack them more effectively. The observed tumor reduction therefore reflects both the direct molecular action of the degrader and the possibility of a secondary antitumor immune response.

The distribution of the compound in the animals provided another important result. Pro-LYTAC was concentrated in tumor tissue, while only small quantities were detected in the liver. The liver is a major site of drug metabolism and clearance, and many therapeutic molecules accumulate there even when the liver is not the intended target. Excessive hepatic exposure can contribute to toxicity and may restrict the dose that can safely be administered. The researchers propose that the locked state of Pro-LYTAC outside the tumor reduces its interactions with healthy tissues and limits the formation of active species in the liver. This could lower the risk of adverse exposure, although detailed toxicology, long-term safety testing and studies in additional animal models will be required before any conclusions about clinical safety can be drawn.

The work also highlights a broader challenge in targeted protein degradation: reaching the right cells is only part of the problem. A degrader may be highly selective for a protein yet still cause toxicity if it remains active while circulating through the body. Conditional activation offers a second layer of control, combining molecular recognition with a biochemical trigger. In the case of Pro-LYTAC, the antibody and glycan components provide the framework for recognition and lysosomal delivery, while the glutathione-sensitive cage is intended to control when that framework becomes operational. Such “prodrug” architectures could eventually be adapted to other tumor-associated signals, including unusual enzyme activity, acidity, oxygen levels or reactive metabolites.

The findings remain an early demonstration in mice rather than evidence of a ready-to-use cancer medicine. Tumors in human patients are chemically and genetically diverse, and glutathione concentrations may vary between tumor types, treatment histories and individual patients. Researchers will need to determine how reliably the cage is removed in human tumors, whether enough active compound reaches malignant cells, how long the degraded protein remains suppressed and whether the immune response can be sustained. They must also assess the possibility of premature activation, immune reactions against the antibody or glycan components, and toxicity caused by unintended protein degradation. Nevertheless, the study presents a compelling route toward safer LYTAC therapy by using the tumor’s own biochemical environment to control drug activity. If the approach can be translated beyond animal models, it may help transform targeted protein degradation from a powerful but potentially broad-acting technology into a more precise weapon against cancer.

Subject of Research: Tumor-selective protein degradation therapy using glutathione-activated Pro-LYTAC for triple-negative breast cancer.

Article Title: “Caged Glycan-Antibody Conjugates for Tumor-Selective Activation of Lysosome-Targeting Chimeras”

Web References: https://doi.org/10.1021/acs.jmedchem.6c01778

References: Journal of Medicinal Chemistry, DOI: 10.1021/acs.jmedchem.6c01778

Keywords

Pro-LYTAC, lysosome-targeting chimera, targeted protein degradation, cancer therapy, triple-negative breast cancer, glutathione, tumor microenvironment, immune evasion, glycan-antibody conjugate, tumor-selective treatment

The work addresses a long-standing challenge in cancer therapy: how to make powerful treatments concentrate inside tumors while limiting damage to healthy tissues. Attenuated strains of Salmonella have attracted interest because they can preferentially accumulate in the abnormal environment of solid tumors. Tumors often contain regions with poor oxygen levels, disorganized blood vessels and local immune suppression, conditions that can support bacterial growth. Once inside these sites, therapeutic Salmonella can act as a biological delivery platform and stimulate immune responses against malignant cells.

The researchers focused on calreticulin, a protein normally found inside the endoplasmic reticulum, where it helps regulate calcium storage and protein folding. Under cellular stress, including stress caused by chemotherapy, radiation or other anticancer treatments, calreticulin can move to the outer surface of a cancer cell. There, it functions as an “eat-me” signal, alerting immune cells that the damaged cell should be engulfed. Because surface-exposed calreticulin is associated with immunogenic forms of cell death, it provides a potential molecular address for directing therapeutic agents toward stressed tumor cells.

The experimental construct combines this targeting concept with L-asparaginase, an enzyme already used in clinical oncology, especially in the treatment of acute lymphoblastic leukemia. L-asparaginase breaks down circulating L-asparagine into aspartic acid and ammonia. Some cancer cells, particularly those with limited capacity to synthesize their own asparagine, depend heavily on the amino acid supplied through the bloodstream. Depleting extracellular asparagine can therefore interrupt protein production, trigger metabolic stress and promote cancer-cell death. The enzyme’s effectiveness, however, can be limited by immune reactions, pharmacological instability and toxicity, making targeted delivery an important goal.

The second component, flagellin, is the structural protein that forms the filament of bacterial flagella. It is also a potent molecular signal for the innate immune system. Immune cells recognize flagellin primarily through Toll-like receptor 5, while intracellular sensing pathways can activate inflammasome components such as NLRC4. These signals can promote the release of inflammatory mediators, stimulate antigen-presenting cells and help convert an immunologically “cold” tumor into one more visible to the immune system. By incorporating flagellin into the therapeutic design, the researchers sought to make the treatment not only directly toxic to tumor cells but also capable of amplifying antitumor immunity.

The study’s central finding was that the calreticulin-targeting L-asparaginase–flagellin conjugate strengthened the antitumor effects of Salmonella-based therapy. Rather than relying on a single mechanism, the treatment brings together several forms of pressure on the tumor. Salmonella can concentrate within the tumor microenvironment, the targeting component can help associate the conjugate with calreticulin-exposing cancer cells, L-asparaginase can deprive vulnerable cells of an essential nutrient, and flagellin can activate immune surveillance. The resulting combination is designed to produce a chain reaction in which metabolic stress and immune stimulation reinforce one another.

This type of combination may be particularly valuable because tumors frequently adapt when exposed to one therapeutic pressure. A cancer cell that survives nutrient deprivation may still be eliminated if immune recognition is intensified. Likewise, an immune response that is too weak to control a tumor may become more effective when bacterial localization and enzyme-mediated damage increase the number of abnormal antigens and danger signals released by dying cells. The researchers’ findings suggest that coordinating these mechanisms can improve the performance of bacteria-assisted cancer treatment in experimental settings.

The approach also reflects a broader shift in cancer research toward programmable biological medicines. Instead of treating bacteria only as infectious threats, scientists are redesigning them as localized delivery vehicles capable of carrying enzymes, immune activators or molecular probes. The advantage is spatial: a therapeutic payload can be produced or concentrated near the tumor rather than distributed uniformly throughout the body. The challenge is equally significant. Any clinical version would need precise control over bacterial attenuation, immune activation, enzyme exposure and potential inflammation, while also demonstrating reliable performance across genetically diverse tumors.

Calreticulin targeting may provide a useful way to address some of that complexity because the protein’s appearance on the cell surface is linked to cellular stress and treatment response. However, the extent and duration of calreticulin exposure can vary between tumor types and individual patients. Future studies will need to determine which cancers are most suitable for this strategy, how calreticulin levels predict treatment response and whether the conjugate can be combined safely with established immunotherapies such as immune-checkpoint inhibitors. Researchers will also need to assess pharmacology, manufacturing consistency and the possibility of immune reactions against the bacterial or enzymatic components.

The findings position the engineered conjugate as a promising experimental platform rather than an immediately available therapy. By merging tumor-homing bacteria with a calreticulin-directed enzyme and an innate immune stimulant, the study illustrates how cancer treatments can be designed to attack malignant cells on multiple biological fronts. If the results are confirmed in further preclinical testing and eventually in carefully controlled clinical trials, this strategy could help turn Salmonella from a passive carrier into an active, multifunctional partner in cancer immunotherapy.

Subject of Research: Calreticulin-targeted L-asparaginase–flagellin conjugate used with Salmonella-mediated cancer therapy.

Article Title: Calreticulin-targeting L-asparaginase-flagellin conjugate enhances Salmonella-mediated antitumor efficacy.

Article References: Nguyen, DH., Afzal, A.R., Nguyen, P.TM. et al. Calreticulin-targeting L-asparaginase-flagellin conjugate enhances Salmonella-mediated antitumor efficacy. Cell Death Discov. (2026). https://doi.org/10.1038/s41420-026-03300-x

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41420-026-03300-x

Keywords: cancer immunotherapy, Salmonella, calreticulin, L-asparaginase, flagellin, tumor targeting, bacterial therapy, antitumor efficacy, immunogenic cell death

Originally designed for advanced medical imaging, C’ dots are ultrasmall fluorescent core-shell silica nanoparticles that have now been repurposed as therapeutic agents. Their ability to selectively target prostate cancer cells relies on conjugation with a prostate-specific membrane antigen (PSMA) homing molecule, ensuring precise delivery of the nanoparticles to malignant cells while sparing healthy tissues. This specificity is critical for minimizing off-target toxicity and maximizing anticancer effects, addressing a longstanding challenge in nanoparticle-based therapies.

The study revealed that C’ dots induce a unique cellular self-destruction pathway called ferroptosis in prostate cancer cells. Ferroptosis is characterized by the iron-dependent accumulation of lipid peroxides, leading to membrane rupture and cell death. While the exact mechanism through which C’ dots trigger ferroptosis remains to be fully elucidated, evidence suggests these nanoparticles capture positively charged iron ions from the bloodstream and transport them into tumor cells, catalyzing oxidative reactions that overwhelm the cellular antioxidant defenses. This multifaceted oxidative assault distinguishes C’ dots from conventional therapies that typically activate only singular death pathways.

Beyond their direct cytotoxicity, C’ dots exert a profound immunomodulatory influence on the tumor microenvironment (TME). Prostate tumors are notoriously “cold,” exhibiting immune cell exclusion or immunosuppressive phenotypes that blunt therapeutic responses. The nanoparticles reprogram immune populations such as T cells and macrophages within the tumor milieu, transforming them from inactive or suppressive states into highly active, tumor-attacking phenotypes. This immune remodeling fosters a “hot” TME conducive to effective immune-mediated tumor clearance.

The immunological reshaping triggered by C’ dots synergizes powerfully with immune checkpoint blockade therapies, which release inhibitory signals preventing T cells from attacking cancer cells. When used in combination, these treatments induced complete or near-complete tumor remissions and durable long-term survival in a substantial proportion of treated mice. Adding a third agent targeting tumor-associated macrophages further amplified these outcomes, highlighting the therapeutic potential of multi-pronged immunometabolic interventions.

Intriguingly, the nanoparticles also disrupted the metabolic homeostasis within various cells of the TME. Tumor progression is often supported by metabolic adaptations in cancer and stromal cells; by interfering with these bioenergetic pathways, C’ dots compound their anti-tumor effects. These complementary metabolic and immunological perturbations underscore the versatile and multifaceted nature of the therapy, which simultaneously targets cancer cell survival, immune response, and tumor metabolism.

Safety evaluations demonstrated that despite transient accumulation in organs such as the spleen, the PSMA-targeted silica nanoparticles exhibited no overt toxicity, reinforcing their promise as clinically translatable agents. This favorable safety profile stems from their specificity, ultrasmall size, and biocompatibility, properties derived from their silicon dioxide composition—a material commonly found in natural food sources and the environment.

The remarkable therapeutic outcomes reported in this study shed light on the underappreciated biological interactions of ultrasmall silica particles with mammalian systems. As Dr. Ulrich Wiesner, co-corresponding author and materials science expert, noted, the evolutionary ubiquity of silica in nature may confer inherent biological compatibilities that remain to be fully understood. This serendipitous connection warrants further mechanistic exploration to unlock additional biomedical applications.

Central to this translational success was a collaborative multidisciplinary effort that combined expertise in oncology, radiology, immunology, materials science, and bioengineering. The joint efforts of investigators like Dr. Michelle Bradbury and Dr. Ulrich Wiesner highlight the power of integrating diverse scientific disciplines to tackle complex challenges in cancer therapy innovation. Postdoctoral fellows, graduate students, and co-authors contributed significantly to elucidating the molecular and cellular underpinnings of C’ dots’ therapeutic action.

Published in the American Association for Cancer Research’s prestigious journal Cancer Research on June 15, 2026, this study represents a pivotal step toward clinical translation. The team is now focused on advancing safety and efficacy evaluations through further preclinical studies and eventually human trials. Their goal is to establish ultrasmall core-shell silica nanoparticles as a new class of dual-function anticancer agents that can reprogram immunometabolic tumor landscapes and overcome resistance mechanisms that have hindered prostate cancer treatment progress.

Dr. Bradbury emphasized that this approach not only tackles tumor cell viability directly but also redefines the immunological contexture of the tumor, a duality that could reset therapeutic paradigms across oncology. As prostate cancer has historically been resistant to immunotherapies, such innovations could finally unlock durable responses for patients who currently have limited options.

In summary, the Weill Cornell Medicine and Cornell engineering collaboration offers a compelling demonstration of how engineered nanomaterials can transcend traditional roles as imaging tools to become potent, multifunctional therapeutics. By inducing ferroptosis and orchestrating a robust antitumor immune environment, these prostate-targeted silica nanoparticles could usher in a new era of personalized and precision cancer medicine.

Subject of Research: Prostate cancer therapy using engineered silica nanoparticles

Article Title: Experimental Treatment Directly Kills Prostate Tumor Cells While Reawakening Antitumor Immunity

News Publication Date: 15-Jun-2026

Web References: https://news.cornell.edu/stories/2021/12/prime-time-first-therapeutic-clinical-trial-cdots-underway

Image Credits: Bradbury Lab

Keywords: Prostate tumors, tumor cells, ferroptosis, immunotherapy, silica nanoparticles, immune checkpoint blockade, tumor microenvironment, metabolic disruption, nanoparticle therapy